June 2025 Quarterly Activities Report and Appendix 4C

June Quarter Update:

Payer-Backed Growth & Real-World Impact

Emyria is rapidly advancing its mission to transform mental health care with standout progress this quarter:

• Landmark Medibank Agreement: Australia’s first private health insurer has backed Emyria for MDMA-assisted therapy for PTSD. This groundbreaking deal validates Emyria’s care model and creates a commercial blueprint for wider adoption and expansion.

• Second Empax Centre Opened: Emyria has doubled clinical capacity with the opening of its second site at Perth Clinic, accelerating access for patients and enabling broader data capture on treatment-resistant PTSD.

• Strong Balance Sheet: With a solid cash position and additional strategic capital secured, Emyria is well-placed to scale both services and data infrastructure to support ongoing growth.

• Real-World Outcomes Driving Demand: Early clinical data shows durable improvements in symptoms and quality of life for complex PTSD patients. These results are fueling insurer and clinician interest, while underpinning future care model enhancements.

• Global Recognition: As one of the only groups with legal access to psychedelic-assisted therapy and a growing real-world evidence base, Emyria is attracting attention from global researchers, media, and strategic partners.

• National Expansion Underway: Emyria is engaging new hospital partners and insurers to replicate its innovative model in new states, with plans to extend services to address more mental health challenges.

Outlook: With payer support and strong patient demand Emyria is pursuing scale and recurring revenue growth in a high-need sector while staying committed to ethical, regulated, and evidence-based psychedelic medicine.